$1.2 Billion Partnership: Key Takeaways

Bristol-Myers Squibb  (NYSE: BMY  ) has been very active in working to establish its leadership in the immuno-oncology arena, with Yervoy's near-blockbuster sales and strong growth last year ($960 million, up 36% year-over-year) a sign of the profits a pharma can derive from this exciting area of cancer treatment. Bristol's next big drug to watch in this area is nivolumab, but Bristol is clearly not interested in putting all of its eggs in one basket.

The company recently signed a deal potentially worth $1.2 billion with CytomX Therapeutics, involving up to four oncology targets using CytomX's Probody platform. In the video below, from Market Checkup, the Motley Fool's health care-focused investing show, health care analysts Michael Douglass and David Williamson discuss the deal and its implications for Bristol's broader oncology pipeline.

Top dividend stocks for the next decade -- Is Bristol one?
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That’s beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor’s portfolio. To see our free report on these stocks, just click here now.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2976085, ~/Articles/ArticleHandler.aspx, 3/30/2015 3:19:37 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...